Company Analysis
Sign in

SNDL Inc. (SNDL)

Nasdaq: SNDL · Medicinal Chemicals & Botanical Products · Edmonton · filing with the SEC since 2019
Full chart Alerts Compare
Grade5.9
◀ Past 6.3● Present 6.5▶ Future 4.6
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
RevenueC$946M+2.8%
Net income-C$15.8M+83.6%
Earnings per shareC$-0.06+83.3%
Operating cash flowC$70.9M+29.1%
CashC$252M+15.5%
Debtn/a
Shareholders’ equityC$1.10B-2.8%
Shares, diluted258.1M-2.3%
Return on equity-1.4%
The recordfrom its filings
Filings in 202623
Newest filingOct 28 · SC TO-C
Annual reportMar 12, 2026
Quarterly reportn/a
Next report due40-F by Apr 30
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents grantedn/a
Filer categoryLarge accelerated filer
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
1819202122232425
As filed, in CAD. Nothing here is a forecast.

News

An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton SNDL · research, not advice